Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
89.4M
-
Number of holders
-
232
-
Total 13F shares, excl. options
-
101M
-
Shares change
-
-181K
-
Total reported value, excl. options
-
$2.41B
-
Value change
-
+$19.8M
-
Put/Call ratio
-
0.41
-
Number of buys
-
123
-
Number of sells
-
-105
-
Price
-
$23.90
Significant Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) as of Q3 2025
285 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2025.
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) has 232 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 101M shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (10.6M shares), BlackRock, Inc. (8.1M shares), ARMISTICE CAPITAL, LLC (6.72M shares), VANGUARD GROUP INC (6.61M shares), MACQUARIE GROUP LTD (4.98M shares), PERCEPTIVE ADVISORS LLC (3.79M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.55M shares), STATE STREET CORP (3.22M shares), FMR LLC (2.89M shares), and Rock Springs Capital Management LP (2.16M shares).
This table shows the top 232 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.